<DOC>
	<DOCNO>NCT02016508</DOCNO>
	<brief_summary>The purpose Phase I/II study investigate safety preliminary efficacy unilateral intravitreally transplantation adult bone marrow stem cell subject geographic atrophy secondary age-related macular degeneration .</brief_summary>
	<brief_title>Safety Study Use Autologous Bone Marrow Derived Stem Cell Treatment Age Related Macular Degeneration</brief_title>
	<detailed_description>This study open-label investigation safety preliminary efficacy unilateral intravitreal injection autologous bone marrow stem cell subject Geographic Atrophy secondary Age-Related Macular Degeneration ( AMD ) . Subjects enrol base specific inclusion/exclusion criterion evaluate regular post transplant interval . Human central nervous system -stem cell transplant vitreoretinal surgeon . The transplantation conduct eye inferior best-corrected visual acuity ( BCVA ) ( i.e. , Study Eye ) . Only Study Eye undergo transplantation . The adult bone marrow stem cell administer vitreous cavity standard surgical approach . Moxifloxacin 300 mg ( per day ) administer orally subject period five day ( 2 day pre post operatively ) . Subjects monitor frequently total one year adult bone marrow stem cell cell injection .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Diagnosis agerelated macular degeneration geographic atrophy ( GA ) Only patient specific degree extent GA eligible Subjects bestcorrected visual acuity ( BCVA ) less equal 20/400 Study Eye No prior current choroidal neovascularization either eye Able provide write informed consent prior study related procedure Agree comply good faith condition study attend require study visit Prior vitreal retinal surgery previous 6 month Glaucoma Atrophic macular disease cause Diabetic retinopathy diabetic macular edema either eye Previous organ , tissue bone marrow transplantation Autoimmune disease Allergy moxifloxacin Current prior malignancy ( chemotherapy )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Adult bone marrow stem cell</keyword>
	<keyword>AMD</keyword>
</DOC>